Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib rollover study in patients with ALK-positive malignancies continuing to benefit from prior Novartis LDK378 studies
CTR20160852Phase 4Active
- Sponsor
- Novartis
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ceritinib in Anaplastic Large Cell Lymphoma ALK-positive, sponsored by Novartis. Started Jun 2017; status: active.
02
Drugs
ceritinib
03
Conditions
Anaplastic Large Cell Lymphoma ALK-positive
Beyond the preview
Go deeper on CTR20160852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160852.